News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 


Genetic markers being used to target oral hepatitis C drug

Please note embargo:

Pharmac_P540c

Genetic markers being used to target new oral hepatitis C drug

A person’s genetic makeup will be used to target a new funded oral treatment for hepatitis C patients from 1 September.

PHARMAC will begin funding boceprevir (Victrelis) from 1 September 2013 for certain patients with the chronic liver infection. Boceprevir will be funded when used as a triple therapy in combination with pegylated interferon with ribavirin.

PHARMAC Medical Director Dr Peter Moodie says many hepatitis C patients do not respond well to current treatments, but that this could improve with the addition of boceprevir.

“Clinical evidence shows that, given the genetic characteristics of a patient, a simple genetic test can fairly accurately predict how they might respond to treatment,” says Dr Moodie.

“There is a group who we know respond poorly to current treatment. They are the ones we think will benefit most from the addition of this new treatment.”

About 25-35% of patients with certain genes showed a sustained response to the currently available treatment of pegylated interferon and ribavirin. By adding boceprevir to the treatment of these patients, the response rate increases to 70–75%.

As well as adding greater effectiveness to available treatments, Dr Moodie says boceprevir is the first funded oral treatment specifically for hepatitis C.

Patients will be genetically tested to determine whether they qualify for boceprevir (in combination with pegylated interferon and ribavirin) as a first-line treatment.

Boceprevir will also be funded for people who have tried but not responded completely to a course of pegylated interferon and ribavirin.

Dr Moodie says though many people live with hepatitis C without ever knowing it, the infection can cause significant health issues including hepatocellular carcinoma, liver failure, which may require a liver transplant.

Pharmacological treatment aims to reduce the likelihood of these transplants being required. In total, PHARMAC expects around 300 patients to start triple therapy in the next year.

In addition to funding boceprevir, PHARMAC has negotiated a price reduction for the Pegasys brand of pegylated interferon with ribavirin. Together, the funding of these hepatitis C treatments will cost $17.8 million over five years, with some of this cost being refunded through confidential rebates negotiated with both suppliers.

ENDS


© Scoop Media

 
 
 
 
 
Culture Headlines | Health Headlines | Education Headlines

 

Howard Davis: Orson Welles' Masterpiece - 'Chimes At Midnight'

Never widely distributed in the US, but Welles' own personal favorite and hugely influential on directors as diverse as Kenneth Branagh and Mel Gibson, a restored 50th anniversary print has now reached the New Zealand Film Festival. More>>

Off To Leeds: Wellington’s Local Naked Girl Spreads Her Wings

Wellington born, bred and based live artist Virginia Kennard, self confessed “local naked girl”, has earned a place on the MA in Performance programme at Leeds Beckett University and flies away in 2 months time. More>>

Free Diving: William Trubridge Breaks World Record

With just a single breath, New Zealand free diver William Trubridge has successfully broken his own unassisted free dive world record of 101 metres. More>>

ALSO:

RLWC 2017 Draw: New Zealand Set For A Festival Of Rugby League

New Zealand Rugby League fans will have the chance to see the Kiwis in action against the best in the Pacific region for the Rugby League World Cup 2017, as announced today at the Official Tournament Draw. More>>

ALSO:

Non-Pokemon News: Magical Park A Safer Augmented Reality For Younger Audiences

Since May, Wellington City Council has been trialling a new app, Magical Park, in collaboration with the game’s New Zealand developer Geo AR Games, in parks around the city. Magical Park uses GPS technology to get users moving around the park to play within a set boundary. More>>

'Erroneous': Pokemon App Makers On Huge Privacy Flaw

We recently discovered that the Pokémon Go account creation process on iOS erroneously requests full access permission for the user's Google account... More>>

ALSO:

Get More From Scoop

 
 

LATEST HEADLINES

 
 
 
 
Health
Search Scoop  
 
 
Powered by Vodafone
NZ independent news